{
    "nct_id": "NCT05372419",
    "official_title": "An Open-Label, 24-Week Study to Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color",
    "inclusion_criteria": "Participants must be ≥12 years of age inclusive, at the time of signing the informed consent/assent.\n\n* Participants who are self-reported race other than White, including but not limited to persons who self-identify as Black or African American, American Indian or Alaska Native, Asian, Native Hawaiian, or Other Pacific Islander.\n* Participants who are Fitzpatrick phototype IV-VI\n* Participants who have chronic AD that has been present for ≥1 year before screening.\n* Have EASI ≥16 at baseline\n* Have IGA score ≥3 (Scale of 0 to 4) at baseline\n* Have ≥10% body surface area (BSA) of AD involvement at baseline\n* Have a history of inadequate response to treatment with topical medications; or determination that topical treatments are otherwise medically inadvisable.\n* Adolescents body weight must be ≥40 kg at baseline.\n* Are willing and able to comply with all clinic visits and study-related procedures and questionnaires.\n* Contraceptive use - Male and/or female\n\n  * Male participants are not required to use any contraception except in compliance with specific local government study requirements.\n  * Female participants of child-bearing potential: must agree to remain abstinent (refrain from heterosexual intercourse) or use a highly effective contraceptive method during the treatment period and for at least 18 weeks after the last dose of study drug. Women of non-child-bearing potential (non-WOCBP) may participate without any contraception requirements.\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.\n* Have a current infection or chronic infection with hepatitis B virus (HBV) at screening, that is, positive for hepatitis B surface antigen (HBsAg) and/or polymerase chain reaction positive for HBV DNA\n* Have a current infection with hepatitis C virus (HCV) at screening, that is, positive for HCV RNA\n* Have an uncontrolled chronic disease that might require multiple intermittent uses of oral corticosteroids at screening (as defined by the investigator).\n* Have uncontrolled asthma that\n\n  * might require bursts of oral or systemic corticosteroids, or\n  * required the following due to ≥1 exacerbations within 12 months before baseline\n\n    * systemic (oral and/or parenteral) corticosteroid treatment, or\n    * hospitalization for >24 hours.\n* Have known liver cirrhosis and/or chronic hepatitis of any etiology.\n* Had prior treatment with dupilumab\n* Had prior treatment with tralokinumab\n* Treatment with topical agents (corticosteroids, calcineurin inhibitors, JAK inhibitors, or phosphodiesterase-4 inhibitors) within 2 weeks prior to baseline.\n* Treatment with any of the following agents within 4 weeks prior to the baseline:\n\n  * systemic immunosuppressive/immunomodulating drugs (for example, systemic corticosteroids, cyclosporine, mycophenolate mofetil, IFN-gamma, azathioprine, methotrexate, and other immunosuppressants);\n  * small molecules (for example, Janus Kinase (JAK) inhibitors);\n  * phototherapy and photochemotherapy for AD.\n* History of malignancy, including mycosis fungoides or cutaneous T-cell lymphoma, within 5 years before the screening, except completely treated in situ carcinoma of the cervix of completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin with no evidence of recurrence in the past 12 weeks.",
    "miscellaneous_criteria": ""
}